Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | METAP1 | P53582 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | CBFB | Q13951 | 1/20 | 0.45 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4337883 | 0.86 | CCR1 (0.50) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL4550924 | 0.81 | KDM4E (0.50) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL29901536 | 0.81 | KDM4E (0.50) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL2322004 | 0.81 | NPC1 (0.69) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL17427076 | 0.81 | KDM4E (0.57) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL5328289 | 0.80 | CCR1 (0.52) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL2562927 | 0.79 | NOTUM (0.46) | NPC1RAB9AALDH1A1GRM5SMN1; SMN2 | |
| SCHEMBL30776779 | 0.79 | KDM4E (0.55) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL13581443 | 0.79 | KDM4E (0.55) | NPC1RAB9AALDH1A1CCR1CCR5 | |
| SCHEMBL25299620 | 0.79 | CCR1 (0.55) | NPC1RAB9AALDH1A1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3988549-A1 | MACROCYCLES WITH HETEROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3099687-B1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-07-04 | — | — | EP | disclosed |
| US-9777001-B2 | Macrocycles with aromatic P2′ groups as factor xia inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-03 | — | — | US | disclosed |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-01-05 | — | — | US | disclosed |
| WO-2015116886-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-08-06 | — | — | WO | disclosed |
| US-7579362-B2 | Aza-bicycloalkyl ethers and their use as alpha7-nAChR agonists | NOVARTIS AG (CH) | 2009-08-25 | — | — | US | disclosed |
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | NOVARTIS AG (CH) | 2007-10-25 | — | — | US | disclosed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249617-A1 | Aza-bicycloalkyl ethers and their use as alpha7-nachr agonists | CHRNA7, CHRNA1, CHRNE | NPC1 3121/4885RAB9A 1741/4885ALDH1A1 1061/4885 |
| US-20170002006-A1 | MACROCYCLES WITH HETROCYCLIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI2, F2, TFPI | NPC1 2295/4885RAB9A 3652/4885ALDH1A1 4748/4885 |
| US-20170096429-A1 | MACROCYCLES WITH AROMATIC P2' GROUPS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, F2 | NPC1 2605/4885RAB9A 3785/4885ALDH1A1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.